The National Cancer Institute is offering funding to support projects focusing on imaging, biomarkers, and digital pathomics to detect premetastatic aggressive cancer and identify precancerous lesions with aggressive potential. This grant aims to improve diagnostic uncertainty by enhancing test sensitivity and specificity through advanced data integration strategies like artificial intelligence. Projects will contribute to the Consortium for Imaging and Biomarkers Research Program, aiming to enhance diagnostic performance, reduce overdiagnosis, and improve cancer detection accuracy. Applications for this grant must be submitted by December 10, 2021.
Opportunity ID: 315474
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-19-264 |
| Funding Opportunity Title: | Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 01, 2019 |
| Last Updated Date: | May 01, 2019 |
| Original Closing Date for Applications: | Dec 10, 2021 |
| Current Closing Date for Applications: | Dec 10, 2021 |
| Archive Date: | Jan 15, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Independent school districts Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other omic data integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving cancer research discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-19-264.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00250597 | Jun 10, 2019 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00259098 | Jun 10, 2019 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00269717 | Oct 28, 2021 | Dec 10, 2021 | View |
Package 1
Mandatory forms
315474 RR_SF424_2_0-2.0.pdf
315474 PHS398_CoverPageSupplement_4_0-4.0.pdf
315474 RR_OtherProjectInfo_1_4-1.4.pdf
315474 PerformanceSite_2_0-2.0.pdf
315474 RR_KeyPersonExpanded_2_0-2.0.pdf
315474 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
315474 RR_Budget_1_4-1.4.pdf
315474 RR_SubawardBudget30_1_4-1.4.pdf
315474 PHS398_ModularBudget_1_2-1.2.pdf
315474 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 2
Mandatory forms
315474 RR_SF424_2_0-2.0.pdf
315474 PHS398_CoverPageSupplement_5_0-5.0.pdf
315474 RR_OtherProjectInfo_1_4-1.4.pdf
315474 PerformanceSite_2_0-2.0.pdf
315474 RR_KeyPersonExpanded_2_0-2.0.pdf
315474 PHS398_ResearchPlan_4_0-4.0.pdf
315474 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
315474 RR_Budget_1_4-1.4.pdf
315474 RR_SubawardBudget30_1_4-1.4.pdf
315474 PHS398_ModularBudget_1_2-1.2.pdf
315474 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
315474 RR_SF424_5_0-5.0.pdf
315474 PHS398_CoverPageSupplement_5_0-5.0.pdf
315474 RR_OtherProjectInfo_1_4-1.4.pdf
315474 PerformanceSite_4_0-4.0.pdf
315474 RR_KeyPersonExpanded_4_0-4.0.pdf
315474 PHS398_ResearchPlan_4_0-4.0.pdf
315474 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
315474 RR_Budget_3_0-3.0.pdf
315474 RR_SubawardBudget30_3_0-3.0.pdf
315474 PHS398_ModularBudget_1_2-1.2.pdf
315474 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
